[go: up one dir, main page]

WO2003004064A3 - Products for treating ovarian cancers and for preventing relapses - Google Patents

Products for treating ovarian cancers and for preventing relapses Download PDF

Info

Publication number
WO2003004064A3
WO2003004064A3 PCT/FR2002/002350 FR0202350W WO03004064A3 WO 2003004064 A3 WO2003004064 A3 WO 2003004064A3 FR 0202350 W FR0202350 W FR 0202350W WO 03004064 A3 WO03004064 A3 WO 03004064A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
products
ovarian cancers
treating ovarian
preventing relapses
Prior art date
Application number
PCT/FR2002/002350
Other languages
French (fr)
Other versions
WO2003004064A2 (en
Inventor
Laurent Poulain
Cathy Staedel
Pascal Gauduchon
Patrick Erbacher
Jean-Paul Behr
Original Assignee
Ct Regional De Lutte Contre Le
Laurent Poulain
Cathy Staedel
Pascal Gauduchon
Patrick Erbacher
Jean-Paul Behr
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Regional De Lutte Contre Le, Laurent Poulain, Cathy Staedel, Pascal Gauduchon, Patrick Erbacher, Jean-Paul Behr, Inst Nat Sante Rech Med filed Critical Ct Regional De Lutte Contre Le
Priority to AU2002329323A priority Critical patent/AU2002329323A1/en
Publication of WO2003004064A2 publication Critical patent/WO2003004064A2/en
Publication of WO2003004064A3 publication Critical patent/WO2003004064A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to products for treating ovarian cancers and for preventing relapses. Said products contain (1) a non-viral nucleic acid vector comprising at least one imine polyethylene (IPE) or a derivative thereof, 2) a nucleic acid sequence comprising the gene bcl-xS or a functional fragment thereof and (3) at least one anti-tumoral agent which is active against ovarian cancer, as a combined preparation for sequential use in the treatment of ovarian cancer, the sequence of nucleic acid associated with said non-viral nucleic acid vector being administered after the anti-tumoral compound.
PCT/FR2002/002350 2001-07-04 2002-07-04 Products for treating ovarian cancers and for preventing relapses WO2003004064A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002329323A AU2002329323A1 (en) 2001-07-04 2002-07-04 Products for treating ovarian cancers and for preventing relapses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/08864 2001-07-04
FR0108864A FR2826869A1 (en) 2001-07-04 2001-07-04 PRODUCTS SUITABLE TO TREAT OVARIAN CANCERS AND PREVENT RELAPSES

Publications (2)

Publication Number Publication Date
WO2003004064A2 WO2003004064A2 (en) 2003-01-16
WO2003004064A3 true WO2003004064A3 (en) 2003-11-06

Family

ID=8865111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/002350 WO2003004064A2 (en) 2001-07-04 2002-07-04 Products for treating ovarian cancers and for preventing relapses

Country Status (3)

Country Link
AU (1) AU2002329323A1 (en)
FR (1) FR2826869A1 (en)
WO (1) WO2003004064A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467599B1 (en) * 2003-04-12 2008-11-26 Eichenauer Heizelemente GmbH & Co.KG Device for the admission of ceramic heating elements and procedure for the production of such
RU2296564C2 (en) * 2005-03-28 2007-04-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Method for treatment of relapses in oncogynecological patients

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834309A (en) * 1993-06-22 1998-11-10 Arch Development Corporation Vertebrate apoptosis gene: compositions and methods
WO2002024232A2 (en) * 2000-09-25 2002-03-28 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834309A (en) * 1993-06-22 1998-11-10 Arch Development Corporation Vertebrate apoptosis gene: compositions and methods
WO2002024232A2 (en) * 2000-09-25 2002-03-28 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BETTINGER T ET AL: "SIZE REDUCTION OF GALACTOSYLATED PEI/DNA COMPLEXES IMPROVES LECTIN-MEDIATED GENE TRANSFER INTO HEPATOCYTES", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 10, 1999, pages 558 - 561, XP000952655, ISSN: 1043-1802 *
CHUNG-HUA FU CHAN KO TSA CHIH [CHINESE JOURNAL OF OBSTETRICS AND GYNECOLOGY], (2000 FEB) 35 (2) 94-7. *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; WANG H ET AL: "Synergistic Efficacy of Adenovirus-mediated bcl - Xs Gene Therapy and Cisplatin in Ovarian Cancer Cell.", XP002193940, retrieved from STN Database accession no. 2002083677 *
KIM, RYUNGSA (1) ET AL: "Enhancement of antitumor effect by intratumoral injection of bax cDNA plasmid in combination with anticancer drugs in gastric tumor in nude mice.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2000) NO. 41, PP. 730-731. PRINT.. MEETING INFO.: 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CALIFORNIA, USA APRIL 01-05, 200, XP002193939 *
RYUNGSA KIM ET AL.: "An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer", J. INFECT. CHEMOTHER., vol. 6, 2000, pages 222 - 228, XP002193938 *

Also Published As

Publication number Publication date
FR2826869A1 (en) 2003-01-10
AU2002329323A1 (en) 2003-01-21
WO2003004064A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
EP1024145A3 (en) Novel azalides and methods of making same
WO2007008463A3 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2007047291A3 (en) Anti-glypican-3 antibody
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2001047507A3 (en) Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound
WO2003080582A3 (en) Fredericamycin derivatives
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
WO2001014579A3 (en) Compositions and methods for delivery of an agent using attenuated salmonella containing phage
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2004046332A3 (en) Amplified genes involved in cancer
WO2001083774A3 (en) Novel mutated form of arginine deiminase
WO2003070755A3 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
WO2003082268A3 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
PL342614A1 (en) Anticarcinogenic drugs
CA2417874A1 (en) Use of ox-2 inhibitors for the treatment of cancer
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
WO2002096348A3 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2002087509A3 (en) Colloidal metal compositions and methods
WO2004073375A3 (en) Podophyllotoxin derivatives as antitumor agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP